Search jobs 28-Apr-2021 Toxys and Unilever Enter Agreement to Further Validate and Expand ReproTracker® for Animal-Free Developmental Toxicity Assessment
Toxys and Unilever Enter Agreement to Further Validate and Expand ReproTracker® for Animal-Free Developmental Toxicity Assessment
Toxys and Unilever will start a collaborative R&D project to further validate and develop the ReproTracker assay, a human cell assay for in vitro teratogenicity testing.
LEIDEN, The Netherlands and BEDFORD, UK, April 28, 2021 / / Toxys and Unilever Safety and Environmental Assurance Centre (SEAC) have entered into an agreement to further validate and expand the ReproTracker assay.
Testing for developmental toxicity according to the current international guidelines requires large numbers of animals, making these tests very resource-intensive and time-consuming as well as raising ethical concerns. The current ReproTracker
Toxys Strengthens Executive Team with Appointment of a CSO
Search jobs Toxys Strengthens Executive Team with Appointment of a CSO
LEIDEN, The Netherlands, February 24, 2021 / B3C newswire / Today, Toxys announces the appointment of Torben Østerlund as Chief Scientific Officer (CSO). Toxys BV is a biotech company based in Leiden, The Netherlands, that provides innovative
in vitro toxicity screening solutions to identify hazardous properties of compounds for the pharmaceutical, chemical, cosmetics and food industries. Toxys developed the ToxTracker, ReproTracker and ToxProfiler assays that provide unique and highly valuable insight into the mode-of-action of toxic substances. With this strengthened leadership, Toxys will further accelerate business growth to become an industry-leader in animal-free chemical safety testing.
Toxys will immediately commercialize and develop further the in vitro reporter technology for mechanistic toxicity testing to improve the human safety assessment of novel medicines, chemicals and cosmetic ingredients.
LEIDEN, The Netherlands, January 28, 2021 / B3C newswire / Toxys, Leiden University and Leiden University Medical Center have agreed immediately to commercialize and also develop further the ToxProfiler technology invented at the two institutions. ToxProfiler allows for rapid toxicity hazard identification of novel and existing drugs, chemicals, and other substances. Furthermore, ToxProfiler has the unique ability to provide detailed and quantitative information about the mode-of-action of such toxic substances. This new technology thereby enormously enlarges the portfolio of toxicity testing that Toxys can make available to the world, complementing the existing genotoxicity and repro-toxicity testing platforms of Toxys.